We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ENB:TSXEnbridge Inc. Analysis

Data as of 2026-03-09 - not real-time

CA$73.30

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Enbridge (ENB.TO) is trading at C$73.3, comfortably above its 20‑day (C$71.7), 50‑day (C$68.0) and 200‑day (C$65.9) simple moving averages, confirming a bullish technical backdrop. The RSI of 64.9 and a bullish MACD histogram (+0.02) reinforce momentum, while the price sits near the identified resistance of C$74.39. Fundamentally, the stock offers a 5.28% dividend yield but the payout ratio exceeds 100% (1.17), raising questions about sustainability despite recent dividend hikes. Revenue growth of 5.9% and operating margins near 18% support cash‑flow generation, yet free cash flow is slightly negative and the debt‑to‑equity ratio is high at 161%, indicating leverage risk. Analyst consensus remains a “buy” with a median target of C$75, implying modest upside (~1.6%) and the DCF model aligns closely with the current price.
The latest news highlights a raised quarterly dividend and a major pipeline expansion, both of which have amplified investor optimism, reflected in an “Extreme Greed” market sentiment (75.9). However, decreasing volume, regulatory scrutiny of pipeline projects, and the elevated payout ratio suggest caution. Overall, ENB presents a blend of income appeal and moderate growth, but investors should monitor earnings coverage and leverage before committing.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with bullish technicals
  • Upcoming Q4 earnings focus on dividend coverage
  • Decreasing volume indicating potential short‑term consolidation

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst median target above current price
  • Pipeline expansion expected to boost cash flow
  • Attractive dividend yield despite payout concerns

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Stable regulated cash‑flow business model
  • High leverage and regulatory exposure
  • Dividend sustainability risk from >100% payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth5.90%
Profit Margin11.49%
P/E Ratio22.8
ROE11.56%
ROA3.38%
Debt/Equity161.40
P/B Ratio2.9
Op. Cash FlowCA$12.3B
Free Cash FlowCA$-239250000
Industry P/E20.6

Technical Analysis

TrendBullish
RSI64.9
SupportCA$67.93
ResistanceCA$74.39
MA 20CA$71.72
MA 50CA$67.99
MA 200CA$65.89
MACDBullish
VolumeDecreasing
Fear & Greed Index75.89

Valuation

Fair ValueCA$21.93
Target PriceCA$74.48
Upside/Downside1.60%
GradeFair
TypeBlend
Dividend Yield5.28%

Risk Assessment

Beta0.08
Volatility21.74%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.